Oral retinoids: efficacy and toxicity in psoriasis. ), has presented Phase III clinical trial data for the treatment of psoriasis and recently became registered for use in the EU. Gollnick HP (1996) Oral retinoidsefficacy and toxicity in psoriasis. Oral retinoids-efficacy and toxicity in psoriasis. Weinstein, GD, Grenn, L. New topical retinoid gel for therapy of psoriasis: close ranging study of AGN 190168.
Learn more about More from psoriasis guideline section 6 at aad.org. The impact of psoriasis on patients’ physical, social, and psychological functioning and health-related quality of life (HRQOL) has been well documented 1 4. Article; Gollnick HP: Oral retinoids efficacy and toxicity in psoriasis. Oral acitretin is currently indicated for the treatment of severe psoriasis in adults, but its use is limited by systemic side effects and teratogenicity. Topical administration of acitretin may lessen the risk of systemic toxicity while increasing local bioavailability in the skin. Oral retinoids efficacy and toxicity in psoriasis.
Active infections (assess the possibility of acitretin toxicity exacerbating infection) Poorly controlled dyslipidemia Metabolic syndrome Uncooperative or noncompliant patient Pediatric or elderly patient (lower tolerance for toxicity?) Absolute contraindications Pregnancy (contraception starting 1 month before treatment and the patient must wait 2 years after cessation to become pregnant) Severe liver failure Severe kidney failure Allergy to drug components. H.P. Gollnick. Oral retinoidsefficacy and toxicity in psoriasis. Oral retinoids–efficacy and toxicity in psoriasis.